SELLAS Life Sciences re-elects directors, approves equity plan increase, but fails to pass officer exculpation amendment

The Company’s stockholders re-elected each of the following nominees as a Class I director to the Board of the Company to hold office until the 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.

The Company’s stockholders ratified the appointment of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

The Company’s stockholders approved the non-binding, advisory resolution on the executive compensation of the Company’s named executive officers.

The Company’s stockholders approved an amendment to the Company’s 2019 Equity Incentive Plan (the “2019 Equity Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2019 Equity Plan by 3,000,000 shares and to delete the reference to the evergreen provision which expired on January 2, 2023 from the 2019 Equity Plan.

The affirmative vote of a majority of all outstanding common stock was required pursuant to Delaware law to approve the amendment to the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. Abstentions and broker non-votes were required to be treated as votes against this proposal. The amendment was not approved because an affirmative vote of all outstanding common stock was not received.